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Atypical hemolytic uremic syndrome (aHUS) is a thrombotic microangiopathy (TMA) characterized by
microangiopathic hemolytic anemia, thrombocytopenia, and acute renal failure. Most cases of aHUS are caused by
uncontrolled complement activation due to genetic mutations in the alternative pathway of complement. More
recently, mutations in the gene of coagulation system have also been identified in patients with aHUS. In Japan,
the recent studies of aHUS have identified the unique genetic characteristics in our country and enabled us to
revise the diagnostic criteria. In this article, we review the classification of TMAs and describe the pathophysiology,
diagnosis, and management of aHUS. We also highlight current progress in clinical and basic research of the
patients with aHUS in Japan.
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Thrombotic microangiopathy (TMA) is defined by a
histological region characterized by microvascular
changes including thrombosis, which results in microan-
giopathic hemolytic anemia, thrombocytopenia, and
organ failure. TMAs are caused by a variety of hereditary
or acquired etiologies, and now broadly classified into
four categories; hemolytic uremic syndrome caused by
Shiga toxin-producing Escherichia coli (STEC) infection
(STEC-HUS), atypical hemolytic uremic syndrome
(aHUS), thrombotic thrombocytopenic purpura (TTP),
and secondary TMA.
Historically, HUS was classified into two forms by the
presence of diarrhea. Ninety percent of HUS arises from
the infection of STEC with severe diarrhea; thus, this
form of HUS was previously named “D (diarrhea) (+)
HUS”, presumably STEC-HUS. On the other hand, the
remaining 10% of HUS was named “D (diarrhea) (−)
HUS”, because it was caused without the infection of
STEC. In 1975, several research groups reported that
this form of HUS could be familial, implicating the
presence of hereditary D(−) HUS [1]. Thus, the term
“atypical HUS (aHUS)” was used to describe the patients
with D(−) HUS and hereditary D(−) HUS. However,
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from uncontrolled complement activation due to genetic
mutations or acquired autoantibodies in the alternative
pathway of complement. These new findings of aHUS
led to differentiate complement-mediated aHUS from
other types of TMA. According to these observations,
currently, the term of aHUS is generally used to describe
complement-mediated aHUS [2–4]. Other TMAs associ-
ated with a variety of causes including infection, drug,
transplant, and pregnancy are now named “secondary
TMA” or etiology-based denomination (e.g., pregnancy
TMA).
Recent advances in understanding pathogenesis of
aHUS have clearly led to differentiate aHUS from other
TMAs and changed the therapeutic approach for aHUS
[5, 6]. However, making a solid diagnosis of this disease
is still not easy due to poor penetrance and lack of
method for identifying excess complement activations.
Moreover, recent studies have also found that the
mutations in the gene of coagulation system predispose
to aHUS leading investigators to reconsider the defin-
ition of aHUS. Our aim in this review is not only to
describe the pathogenesis, diagnosis, and management
of aHUS but also to improve the evidence-based practice
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HUS due to Shiga toxin-producing bacteria is most
frequently formed and is generally called STEC-HUS (or
HUS or typical HUS). Although STEC-HUS occurs at any
age, children can be predominantly affected. Severe
abdominal pain, diarrhea, and bloody stools are common
findings, which appeared several days after taking contam-
inated foods. The progression to HUS is related to the
binding of Shiga toxin to the target cell surface via globo-
triaosylceramide, which leads to cytotoxic effect via inhib-
ition of protein synthesis and apoptosis. Moreover, the
presence of Shiga toxin also induces the secretion of
unusually large von Willebrand factor (VWF) from endo-
thelial cells [7]. Prognosis of STEC-HUS is favorable with
90% of child cases being recovered, but 1–2% of patients
die during acute phase, and 12% of patients, who recov-
ered from STEC-HUS once, die or progress to end-stage
renal disease (ESRD) in long-term follow-up [3, 8].
TTP results from severe deficiency of a disintegrin-like
and metalloprotease with thrombospondin type 1 motif,
13 (ADAMTS13), which is a specific cleaving protease
of VWF. ADAMTS13 deficiency leads to the secretion
of unusually large VWF from vascular endothelial cells,
thus leading to the VWF-dependent platelet adhesion in
small vessels. Homozygous or compound heterozygous
mutations of ADAMTS13 are the cause of hereditary
TTP [9, 10]. Moreover, acquired TTP arises from auto-
antibodies against ADAMTS13 [11].
A link between complement system and aHUS has
been highlighted since the 1970s [12], and subsequent
study identified that genetic mutation of complement
factor H (CFH), a major complement regulatory factor, is
associated with pathophysiology of aHUS [13]. Since
then, various genetic mutations in multiple complement
factors belonging to alternative pathway have been found
in 60% of patients with aHUS. Two types of variants are
associated with this disease; one is loss-of-function
mutation of the complement regulatory factors, and the
other is gain-of-function mutation of complement itself
or complement activation factors. Of note, autoanti-
bodies against CFH also predispose to aHUS. These gen-
etic or acquired defects result in excess complement
activation on the cell surface, leading to endothelial
damage, inflammation, and thrombosis formation. More
recently, a link between coagulation system and aHUS
has also been highlighted.
Secondary TMA arises from diverse factors and
diseases (metabolic disorder, infection, drug, pregnancy,
autoimmune disease, systemic disease, hematopoietic
stem cell transplantation/solid organ transplantation,
malignant hypertension, and malignancy). In pediatric
cases, both Streptococcus pneumoniae infection and Co-
balamin C deficiency are highly related to the cause of
secondary TMA. In contrast to STEC-HUS, aHUS, andTTP, the pathogenesis of secondary TMA is still unclear.
Especially, the distinction between aHUS and secondary
TMA is sometimes not clear. In fact, complement gen-
etic mutations or anti-CFH autoantibodies have been
found in a part of patients with post-transplant-
mediated TMA [14] and patients with hemolysis, ele-
vated liver enzyme, low platelet count (HELLP) syn-
drome [15, 16]. It is unclear whether aHUS is underlying
the disease or not in these cases; thus, more studies are
needed to confirm these findings.
In Japan, the classification of TMAs was originally de-
scribed in a diagnostic criteria for aHUS proposed by
the Joint Committee of the Japanese Society of Nephrol-
ogy and the Japan Pediatric Society in 2013 [17, 18]. In
this criterion, aHUS was defined as TMA excluding
STEC-HUS and TTP; therefore, TMA caused by a var-
iety of etiology, now named secondary TMA, was also
included in the category of aHUS. This classification has
led to the early diagnosis of aHUS and timely initiation
of treatment. However, the term of aHUS is now gener-
ally accepted to describe only complement-mediated
aHUS as described above. To address this situation, the
Joint Committee developed a novel guideline for aHUS
including recommendation for treating this disease in
2016 [19, 20]. This guideline redefined aHUS as TMA
caused by complement dysregulation, and the exclusion
of secondary TMA is needed for diagnosing aHUS in
addition to the exclusion of STEC-HUS and TTP
(ADAMTS13 <10%). Current problem of this field is
that there are some cases of aHUS among secondary
TMA [14, 21]; however, there are no crucial clinical
characteristics and laboratory parameters to distinguish
them. To overcome this problem, further research
regarding both clinical characteristics and laboratory
biomarkers and the establishment of rapid genetic
diagnostic system for aHUS are required.
We hope that this novel guideline will improve the
understanding of physiopathology and diagnosis of indi-
vidual TMA, leading to a rapid and correct diagnosis, and
more judicious treatment for individual cases in Japan.
Epidemiology
aHUS is considered a rare disease, but its incidence is
not known precisely. The annual incidence of aHUS is
estimated to be two cases per million in the USA [22],
and the prevalence are reported to be 3.3 per million
among patients below the age of 18 [5]. More recently,
the research group from France reported an incidence of
0.23 cases per million [23]. aHUS affects at any age, and
approximately half of this disease usually occurs before
the age of 18, without sex difference [24]. Although, the
epidemiology of patients with aHUS in Japan has not
been well clarified, based on our cohort study, 100 to
200 patients seem to have been diagnosed.
Fig. 1 Alternative pathway of complement. CFH complement factor
H; CFI complement factor I; MCP membrane cofactor protein; C3
complement component C3; CFB complement factor B; CFD
complement factor D; MAC membrane attack complex
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The complement system is an essential component of
innate immunity for protecting host from invading path-
ogens. Complement system, which consists of over 30
proteins, can be mostly present as inactivated forms, and
the activation of it is caused through three main path-
ways; classical pathway, alternative pathway, and lectin
pathway. These three pathways promote the formation
of C3 convertase, which degrades C3 into C3a and C3b.
The C3b molecule functions as a major opsonin, and
binds covalently to pathogens or to any surface. The
binding of C3b to Gram-positive bacteria leads to the
phagocytosis by neutrophils, macrophages, and mono-
cytes. In the case of Gram-negative bacteria, bound C3b
induces the progression of complement cascade and the
generation of the lytic membrane attack complex. The
activation of the classical and the lectin pathways is initi-
ated by the recognition of invading microorganisms via
the Fc moieties of antigen-bound antibody or mannose-
binding lectin, respectively. On the other hand, the acti-
vation of alternative pathway needs no specific initiator.
The activation process of alternative pathway is illus-
trated in Fig. 1. In the alternative pathway, C3 is easily
converted to C3(H2O) and rapidly reacted with comple-
ment factor B (CFB) and complement factor D (CFD).
This reaction leads to the formation of C3(H2O)Bb, which
works as an initial fluid phase C3 convertase and prompt
to generate more C3b. This spontaneous activation system
called “tick over” is potentially dangerous; thus, it is
strictly controlled by complement regulatory factors in-
cluding CFH, complement factor I (CFI), and membrane
cofactor protein (MCP). Generally, C3(H2O)Bb or C3b is
rapidly and proteolytically inactivated by CFI collaborated
with CFH in the fluid phase. On the self-cell surface like
endothelial cells, CFH also acts as a complement regulator
by binding to sialic acids or sulfated glycosaminoglycans
on self-surface via its C-terminal basic domains. A trans-
membrane protein MCP helps to inactivate C3b by CFI.
Thrombomodulin (THBD), a transmembrane protein,
which generates anticoagulant active protein C to reduce
blood coagulation, is also associated with the downregula-
tion of alternative pathway by accelerating CFI-mediated
inactivation of C3b. On the other hand, once C3b binds to
pathogens lacking complement regulatory proteins, bound
C3b preferentially reacts with CFB and CFD, which results
in formation of a C3 convertase and generating more C3b.
The C3 convertase can recruit another C3b to form
C3bBbC3b (C5 convertase), which generates a potent
anaphylatoxin C5a through cleavage of C5. The binding
of C5b to C6, C7, C8, and C9 causes the formation of
membrane attack complex (C5b–9) for eliminating
pathogens.
Several research groups have shown that approxi-
mately 60% of patients with aHUS have mutations incomplement regulatory or complement factors in the
alternative pathway (CFH, CFI, MCP, THBD, C3, and
CFB). Loss of function mutations in complement regula-
tory factors (CFH [13, 25–27], CFI [28, 29], MCP [30, 31],
and THBD [32]) cause the impairment of inactivating
C3b both on the cell surface and fluid phase. On the
other hand, gain of function mutations in complement
activation factors, C3 and CFB reduce the binding affin-
ity for CFH and/or MCP leading to impaired CFI-
mediated inactivation [33–36]. These aHUS-associated
mutations cause excess complement activation on host-
cell surface leading endothelial damage. Moreover,
combined mutations in the foregoing six genes seem to
increase susceptibility to aHUS [37]. Acquired autoanti-
bodies against CFH have been identified in 5–10% of pa-
tients with aHUS [38–40]. These antibodies are highly
associated with the alteration in CFH-related (CFHR)
genes. The genes encoding the five CFHR (CFHR1-5)
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repeat regions having a high sequence identity. Thus,
these regions occur nonallelic homologous recombin-
ation leading to the deletion or duplication within CFH
and CFHR genes. Notably, homozygous gene deletion of
CFHR1 is specifically linked with the production of auto-
antibodies against CFH [39–41]. A majority of these
antibodies recognize the C-terminal region of CFH and
inhibit the complement regulatory function of CFH on
the cell surface [42]. Moreover, nonallelic homologous
recombination of CFHR gene region predisposes to the
formation of hybrid gene of CFH-CFHR, which causes
aHUS [6].
Currently, several research groups have shown the cor-
relation between coagulation system and aHUS. In 2013,
Lemaire et al. have identified that the homozygous or
compound heterozygous mutations in the diacylglycerol
kinase epsilon (DGKE) gene in 13 aHUS patients who
belong to nine unrelated families by whole-exome se-
quencing [43]. DGKE is a lipid kinase family protein,
and is expressed in endothelium, platelets, and podo-
cytes. The underlying pathology of DGKE-associated
aHUS is still unclear, but one possibility is that the loss
of function of DGKE results in upregulation of pro-
thrombotic factors and platelet activations. It is still de-
batable whether DGKE-associated aHUS is linked with
complement activation or not.
More recently, one published paper has identified four
genetic variants in the gene of plasminogen in the pa-
tients with aHUS, and three of these variants were
known plasminogen deficiency mutations [44]. Miyata
et al. have shown that one genetic variant p.Ala620Thr
in plasminogen, which is commonly observed in the
northeast Asian populations including Japanese and
causes dysplasminogenemia, is not predisposing variant
for aHUS [45]. Further studies are required to confirm
whether the coagulation system is additional pathogen-
esis for aHUS or not.
In addition to disease-associated mutations mentioned
above, some environmental factors are related to in-
crease the risk of developing aHUS. The onset of aHUS
seems to be facilitated by various triggers such as infec-
tion and pregnancy [14, 24]. One retrospective study has
shown that 21 of 100 adult female patients with aHUS
developed pregnancy-associated TMA mainly in post-
partum period [46].
Diagnosis of aHUS
Clinical diagnosis of aHUS
Rapid diagnosis of aHUS is critical for early initiation of
treatment that prevents the patient’s kidney from ESRD.
Clinically, initial diagnosis of aHUS is made by microan-
giopathic hemolytic anemia (Hb <10 g/dL, negative direct
Coombs test, elevated LDH, decreased haptoglobin, andthe presence of schistocytes), thrombocytopenia (platelet
count <150 × 109/L), and renal failure (elevated serum cre-
atinine, low glomerular filtration rate, proteinuria, and
hematuria). Other diseases which show similar clinical
presentation to TMA such as disseminated intravascular
coagulation or heparin-induced thrombocytopenia should
be carefully excluded. In patients with aHUS, the major
target organ is the kidney, but the heart, lungs, gastro-
intestinal tract, pancreas, and brain can also be affected.
Although the presence of diarrhea is a representative
manifestation of STEC-HUS, it has also been identified in
10–30% of aHUS patients [14, 24].
To differentiate aHUS from TTP, the activity of
ADAMTS13 should be measured before the initiation of
plasma therapy. Severe deficiency of ADAMTS13 activity
(<10%) is common findings in patients with TTP. One
study of 214 patients with TMA has shown that severe
low platelet count (<30 × 109/L) and serum creatinine
(<2.26 mg/dL) were commonly detected in 157 of 160
patients with patients having severe ADAMTS13 defi-
ciency [47] implicating that kidney damage is not gener-
ally severe in TTP. Of note, these laboratory data do not
always differentiate aHUS from TTP. The confirmation of
STEC-HUS needs the direct detection of Shiga toxins in
feces and anti-lipopolysaccharide immunoglobulin M anti-
body measurements. Moreover, the screening of various
diseases or specific laboratory data associated with TMA
is critical for diagnosing secondary TMA.
Complement assessment in aHUS
To confirm the clinical diagnosis of aHUS, a variety of
specific diagnostic tests are recommended as follows:
quantification of complement components (C3 and C4),
regulators (CFH, CFI, MCP, and CFB), and complement
activity (CH50 for classical pathway, AP50 for alternative
pathway), screening of anti-CFH autoantibodies, and
genetic test of candidate gene (CFH, CFI, MCP, C3, CFB,
THBD, and DGKE) [5]. The low level of C3, but not C4,
may reflect the excess activation of the alternative path-
way, but only 30–40% of patients with aHUS show a low
level of C3 [14, 23]. Thus, a normal C3 level does not
exclude the diagnosis of aHUS. Similarly, normal levels
of abovementioned complement factors do not rule out
the diagnosis of aHUS, because a majority of mutations
cause functional impairment instead of quantitative de-
fects. The hemolytic assay can be used to assess the
CFH function [48–50]. In this assay, patient specimens
are incubated with sheep red blood cells (RBCs) that
have been known as “non-activating cells” leading no
amplification of C3b on its cell surface. CFH is a major
complement regulatory factor in the alternative pathway,
and consists of 20 short consensus repeats (SCRs) with
each about 60 amino residues. CFH is capable of pro-
tecting sheep RBCs from complement-mediated lysis via
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expressed on surface of sheep RBCs. Thus, CFH muta-
tions or anti-CFH autoantibodies having a defect in the
protection of cell surfaces lyse the sheep RBCs [50]. The
anti-CFH autoantibodies are generally measured by
ELISA. Although several ELISA methods have been
reported, Watson et al. have recommended the use of
the Paris method, which is the most robust, cost-
effective, and easy to establish [51].
Various biomarkers have been studied to reveal the
underlying complement perturbations of aHUS to differ-
entiate it from other TMAs. The significantly increased
levels of C5a and soluble C5b-9 (sC5b-9), markers of ter-
minal complement activation, have been identified in the
acute phase of aHUS compared with TTP or healthy
controls [52, 53]. Moreover, urine C5a, sC5b-9, and alter-
native pathway activation marker Ba are elevated in acute
phase of aHUS, and these markers are decreased by eculi-
zumab administration, with the exception of Ba [54].
However, Noris et al. has reported that plasma C5a and
sC5b-9 were not suitable markers for diagnosing aHUS,
because these values were normal in 9 out of 19 cases
even during the acute phase [55]. Recent study has de-
scribed a new technique for detecting excess complement
activation by using modified HAM test, which is classic-
ally used to diagnose the patients with paroxysmal noctur-
nal hemoglobinuria (PNH). Gavriilaki and their colleagues
have established the GPI-anchored protein-deficient cells,
that is, PNH-like reagent cells [56]. When this cells are
treated with the serum from TMA patients, significantly
reduced cell viability are found in aHUS, compared to
TTP. This novel method might be used for rapid diagnosis
for aHUS to differentiate it from other TMAs.
Degradation of C3 spontaneously occurs after blood
collection, which leads to altered complement state in
patient specimens. To avoid pre-analytical errors, blood
samples should be immediately centrifuged, and serum
or plasma should be stored at −80 °C. EDTA plasma is
generally used for measuring C5a, sC5b-9, and Ba but
cannot be used for measuring ADAMTS13 activity,
which can be only determined by using citrated plasma.
Storage of EDTA plasma, citrated plasma, and serum
before therapy is critical for accurate hemolytic assess-
ment of underlying complement profile in patients sus-
pected with aHUS.
Genetic test
Genetic screening is needed to confirm the clinical diag-
nosis of aHUS. Direct sequencing of six candidate genes
(CFH, CFI, MCP, C3, CFB, and THBD) should be per-
formed to reveal the predisposing mutations associated
with aHUS. The screening of DGKE mutations is also
recommended for the patients with onset of aHUS be-
fore the age of 1–2 years. Multiple ligation-dependentprobe amplification is generally used to identify the copy
number variations of the genes encoding CFHR proteins.
As shown in the recent finding of DGKE mutations,
next-generation sequencing analysis is helpful to reveal-
ing the undiscovered disease-associated genes in aHUS.
Causality between genetic variants and the develop-
ment of aHUS should be carefully assessed. A recent im-
portant study has shown that 122 of 406 (27%)
mutations, which were published as disease-associated
mutations in 104 individuals were either common poly-
morphisms or lacked direct evidence for pathogenicity
[57]. Guidelines for genetic analysis have stated the im-
portance of the terms to describe the genetic variants,
and recommended the careful assessment to differenti-
ate disease-causing genetic variants from many variants
of human genome. To avoid the false-positive reports of
causality, various mutations detected in aHUS should be
carefully studied, and correctly named by using appro-
priate nomenclature (e.g., pathogenic, likely pathogenic,
uncertain significance, likely benign and benign) instead
of simple term like “causative” or “no causative” [58].
Genetic background of aHUS is complicated because
of its various hereditary forms (autosomal dominant or
autosomal recessive manner) and poor penetrance
(about 50%). Therefore, individual and families should
be provided an opportunity for genetic consultation by
physicians, genetic professionals, and genetic counselors.
Patient and patients’ family members should be provided
the following information: (1) the hereditary forms of
aHUS and the importance of genetic test in the patients’
parents, siblings, and offspring, (2) the risk of aHUS in
the patient’s parents, siblings, and offspring, and (3) the
risk of aHUS during pregnancy or after delivery.
Treatment for aHUS
Plasma treatment
Since 1980s, plasma infusion (PI) or plasma exchange
(PE) had empirically been considered as the first choice
for the treatment of aHUS. PI with fresh frozen plasma
serves functional complement regulatory factors. In
addition to this effect, PE is presumed to remove the ab-
normal complement related factors like mutant proteins
or anti-CFH antibodies. There are no prospective clinical
trial data, but the introduction of plasma therapy has de-
creased the mortality of patients with aHUS and
achieved hematological remission in 70% of patients
with aHUS. On the contrary, plasma therapy resulted in
ESRD or death in 48% of pediatric and 67% of adult
cases died or reached ESRD within 3-year follow-up
[14]. Especially in aHUS patients with CFH or CFI muta-
tions, complete hematological remission or renal recov-
ery rates was low.
Although some patients do not achieve complete
remission by plasma therapy, it is still an important
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aHUS. Early initiation of plasma therapy followed by
maintenance PI/PE could be effective for attaining
hematological remission and preserving renal function.
However, evaluation of other TMAs and the diagnosis of
aHUS take some times in practical situations. Of note,
the efficacy of plasma therapy is uncertain in the treat-
ment for STEC-HUS. In the case of secondary TMA,
the necessity and efficacy of plasma therapy depends on
the coexisting disease, and PE should be avoided in the
cases with S. pneumoniae-mediated TMA. Concomitant
immunosuppression and plasma therapy may allow bet-
ter outcomes by reducing antibody titers in the case of
anti-CFH antibody positive patients. So far, combined
therapy of PE and immunosuppression (steroids with or
without immunosuppressants such as cyclophosphamide
or rituximab) for the induction and maintenance therapy
with steroids and immunosuppresants (mycophenolate
mofetil or azathioprine) have been reported to be favor-
able [5, 59, 60]. Eculizumab also seems to be effective in
anti-CFH antibody aHUS patients [5]. However, the op-
timal treatment combination for anti-CFH antibody
positive patients remains to be elucidated in the future.
Catheter-related complications should be concerned in
pediatric cases, and PI may be recommended when PE is
technically difficult to perform. Plasma therapy should
be tapered based on increased platelet count, improve-
ment of hemolysis, and lactate dehydrogenase level.
Eculizumab
Eculizumab, a monoclonal humanized antibody against
C5, was originally approved for treating the patients with
PNH. This antibody specifically binds to C5 and blocks
the terminal complement activation by inhibiting the
cleavage of C5 into C5a and C5b. The efficacy and safety
of eculizumab for the treatment of aHUS have been
reported since 2009 [61–63], and both the USA Food and
Drug Administration and the European Medicines Agency
approved the indication of aHUS in the treatment of
aHUS in 2011. Subsequent reports also showed that the
use of eculizumab was effective for the patients with
aHUS who underwent the renal transplantation [64].
In pediatric cases, eculizumab administration is rec-
ommended as a first-line therapy when the diagnosis of
aHUS is made, because these patients have a high risk of
catheter-related complications and a lower incidence of
secondary TMA than adults. Contrary, in adult patients,
the initial choice of PE or eculizumab is often difficult
because adults have higher incidence of secondary
TMA, some secondary TMA have the indication of PE,
and currently eculizumab is not approved for secondary
TMA in our country. The authors recommend evaluat-
ing STEC-HUS, TTP, and secondary TMA before the
initial use of eculizumab. In adult cases, eculizumabadministration may be recommended as a first choice in
the following situations: (1) the patients have repeated
episode of aHUS or family history (especially, one or
more family members have renal failure caused by
TMA), (2) the patients are already diagnosed with aHUS,
and (3) the probability of the diagnosis of aHUS is high.
Although the reports are limited, eculizumab treatment
for aHUS during pregnancy stabilizes clinical and la-
boratory markers and shows no overt safety issues [65].
However, further investigations are needed to ascertain
the efficacy and safety of eculizumab in the treatment of
the patients with aHUS during pregnancy.
The appearance of eculizumab opened a new era for
treatment of aHUS; however, it is still unclear how long
eculizumab therapy should be continued. Eculizumab
treatment requires the patients to visit the hospital once
every 2 weeks, which may lead to the impaired quality of
life. Moreover, lifelong treatment may cause the compro-
mised vascular access. The extremely high cost of eculi-
zumab is also important limitation of this drug. The
current report concerning the eculizumab withdrawal
has shown that 24 patients discontinued the treatment,
and 6 out of 24 patients (25%) had recurrence at the
time of publication [66]. Four of these six patients had
CFH mutation or anti-CFH antibodies, suggesting that
the patients having CFH-related abnormalities were fre-
quently associated with the recurrence of aHUS [5, 66].
On the other hand, patients with MCP mutation, CFI
mutation, or no mutation showed no recurrence. Al-
though more studies are needed to confirm these obser-
vations, lifelong treatment may not be needed for all
patients with aHUS, and clarifying the genetic back-
ground may help to discontinue the anti-complement
drug [67].
Prognosis
Before the use of eculizumab for treating aHUS, a poor
prognosis of this disease has historically been described,
with higher than 50% mortality and ESRD. The clinical
outcomes vary depending on the genetic alterations
[14, 24]. The worst prognosis is the patients with CFH
mutations, with over 50% mortality or ESRD rates within
1 year from the first episode of aHUS [14, 24]. On the
contrary, the cases of the patients with MCP mutations
have a good prognosis; none of the children and only
25% of adults reached to ESRD at first episode although
they have a high risk of relapse [2]. Of note, these data
come from the historical studies treated with plasma
therapy [14, 23, 24]. Recent advances of therapy includ-
ing early initiation of plasma therapy or eculizumab ad-
ministration significantly improved the mortality and
prognosis of aHUS [62, 68]. In the near future, the data
showing prognosis of aHUS patients depending on the
genetic background treated with eculizumab will be
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control is also important as short- and long-term treat-
ment; however, the effects of different antihypertensive
drug classes remain to be elucidated.
Current studies for the patients with aHUS in Japan
Since the early 2000s, some patients with clinically sus-
pected aHUS have been identified in Japan. In 2008,
Mukai et al. reported the predisposing mutation of CFH
in a 1-year-old female aHUS patient by using both
hemolytic assay and genetic analysis [69]. Further study
was performed by Fujimura et al., who have studied Jap-
anese patients with TMA by measuring ADAMTS13 ac-
tivity since 1998. In 2009, they reported the
characteristics of 919 TMA patients and noted that 24
of 919 were suspected to be “congenital aHUS” because
of having repeated and familial TMA episodes with
ADAMTS13 levels of more than 10% [70]. To reveal the
underlying pathogenic mechanisms of these patients,
they established the diagnostic system for aHUS (the
quantitative hemolytic assay, the screening of anti-CFH
antibody, and the genetic tests of CFH, CFI, MCP, C3,
CFB, and THBD) [45, 50, 71, 72]. In the hemolytic assay,
Yoshida et al. [50] produced inhibitory monoclonal anti-
bodies against CFH and used one of these antibodies as
a positive control, which enabled to quantitatively calcu-
late the degree of hemolysis in patient plasma. They re-
vealed that patient plasma with CFH mutation or anti-
CFH autoantibodies had >50% hemolysis. In addition,
patient plasma with the C3 p.K1105Q mutation posi-
tioned at the CFH binding interface also showed >50%
hemolysis.
The genetic analysis of 45 patients with aHUS has shown
that the frequency of C3 mutation (43%) was greater than
that in Western countries (2–10%). In contrast, only 7% of
patients with aHUS carried the CFH mutations in Japan,
which is much less than the frequency reported by Western
countries [50]. Interestingly, about 80% patients with C3
mutations have the same variants of I1157T, and the pa-
tients carrying this variants were only found in an ex-
tremely restricted area (Kansai district including Mie, Nara,
Kyoto and Osaka prefectures) of West Japan [50, 73]. These
observations suggested that the genetic background of
aHUS in Japan differs from that of Western countries.
However, because study population was small and 60% of
the patients with aHUS were from West Japan, further as-
sessments are required to reveal the genetic characteristics
in Japan. Complement-related genes have also been investi-
gated in the patients with congenital TTP having renal
damage by Fan et al [74]. Six complement and complement
regulatory genes of aHUS were sequenced, and they have
suggested that rare predisposing complement genetic muta-
tions of aHUS do not contribute to renal insufficiency in
congenital TTP patients.In 2013, the use of eculizumab was approved for treat-
ing complement-mediated aHUS patients by Ministry of
Health, Labour and Welfare in Japan. Several case re-
ports have described the efficacy and safety of this drug
for aHUS in Japan. Ito et al. have retrospectively ana-
lyzed the clinical course of 10 pediatric aHUS cases
treated with eculizumab, and shown that all patients
achieved the rapid hematological remission with with-
drawal from plasma therapy [75]. Ohta et al. have re-
ported that one infant patient with compound
heterozygous DGKE mutation, who significantly recov-
ered from severe hypertensions and peritoneal dialysis
by eculizumab administration [72, 76]. Of note, this pa-
tient showed the severely decreased level of C3 suggest-
ing unregulated complement activation; however, it is
unclear whether the mutation in DGKE is associated
with exhausted C3 or not in this particular patient. In
contrast to pediatric cases with aHUS, little has been re-
ported on adult cases in Japan. The study published by
Okumi et al. has shown one male patient with CFH mu-
tation, who received living-related kidney transplant
after first episode of aHUS [77]. This patient developed
aHUS again after transplantation, but his hematological
parameters and renal function was fully recovered by
initiation of eculizumab treatment.
Currently, the diagnostic system of aHUS was moved
from Nara Medical University to the Division of Neph-
rology and Endocrinology, the University of Tokyo Hos-
pital. Protein-based analyses (the hemolytic assay and
the screening of anti-CFH autoantibodies) are performed
in the University of Tokyo Hospital, and the DNA ana-
lyses of six candidate genes (CFH, CFI, MCP, C3, CFB,
and THBD) are in National Cerebral and Cardiovascular
Center. Moreover, epidemiologic study of aHUS is on-
going in the University of Tokyo Hospital. Consultation
for diagnostic test of aHUS is available by e-mail (ahus-
office@umin.ac.jp).Conclusions
The recent progresses in the field of aHUS during the
last two decade have significantly clarified the under-
lying pathology of aHUS, which led to new era for
complement blockade; eculizumab therapy. Early ad-
ministration of eculizumab has dramatically prevented
the progression to ESRD in the patients with aHUS.
In Japan, an established structured diagnostic system
of aHUS has gradually revealed both clinical charac-
teristic and genetic background of this disease. On
the other hand, the data on the prognosis (risk of
ESRD, death, relapse, and recurrence after renal
transplantation) or outcome of eculizumab therapy
still have not been well documented. Now, our groups
are addressing these issues, and we hope that this
Yoshida et al. Renal Replacement Therapy  (2017) 3:5 Page 8 of 10ongoing study will lead to early diagnosis and appro-
priate treatment for patients with aHUS in Japan.
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